MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.10), FiscalAI reports.
MoonLake Immunotherapeutics Stock Down 7.3%
Shares of MoonLake Immunotherapeutics stock traded down $0.84 during trading hours on Thursday, hitting $10.71. The company had a trading volume of 832,434 shares, compared to its average volume of 1,532,785. The company has a debt-to-equity ratio of 0.23, a current ratio of 12.56 and a quick ratio of 12.56. The company’s 50-day moving average is $12.28 and its two-hundred day moving average is $16.38. The company has a market cap of $911.95 million, a P/E ratio of -2.81 and a beta of 1.14. MoonLake Immunotherapeutics has a twelve month low of $9.46 and a twelve month high of $23.29.
Analyst Ratings Changes
A number of analysts have issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, September 16th. Weiss Ratings upgraded MoonLake Immunotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 21st. Wall Street Zen cut MoonLake Immunotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, September 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday, October 5th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $28.50.
Read Our Latest Stock Report on MoonLake Immunotherapeutics
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. The company is advancing medicines designed to address conditions in which the immune system contributes to chronic inflammation and tissue damage.
Its lead product candidate is sonelokimab, an investigational Nanobody-based therapy designed to selectively inhibit interleukin-17A and interleukin-17F, two cytokines involved in inflammatory disease.
Read More
- Five stocks we like better than MoonLake Immunotherapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
